{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["PAZIENTI CON METASTASI EPATICHE COLORETTALI NON SUSCETTIBILI DI CHIRURGIA","Liver metastases","PATIENTS WITH LIVER COLORECTAL METASTASES NOT CANDIDATED TO SURGERY"],"disease":["Patients With Liver Colorectal Metastases Not Candidated To Surgery","Pazienti Con Metastasi Epatiche Colorettali Non Suscettibili Di Chirurgia","Liver Metastases"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2530668"],"location":["Italy"],"study_start_month":["4"],"keyword":["ERBITUX*INFUS 1FL 50ML 5MG/ML"],"repository":["ECRIN MDR"],"study_status":["Ongoing"],"additional_accession":[]},"is_claimable":false,"name":"Tumour markers response to chemotherapy in patients with colorectal liver metastases","description":"Primary objectives: COMPLETE LIVER RESECTION AFTER CHEMOTHERAPY\nPrimary endpoints: COMPLETE RESECTION OF LIVER METASTASES","dates":{"creation":"2012-04-15"},"accession":"2530668","cross_references":{"EU Clinical Trials Register":["2012-000834-21"]}}